Aktis Oncology, Inc. (AKTS) vs Amphastar Pharmaceuticals, Inc. (AMPH)

A side-by-side comparison of Aktis Oncology, Inc. and Amphastar Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Aktis Oncology, Inc. logo
AKTS
Aktis Oncology, Inc.
$975M
$18.26HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Amphastar Pharmaceuticals, Inc. logo
AMPH
Amphastar Pharmaceuticals, Inc.
$1.11B
$25.16HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT

Total return — AKTS vs AMPH

growth of $100 · dividends reinvested · last 1y
AKTS -17.3% (-17.3%/yr)AMPH -8.1% (-8.1%/yr)AMPH compounded faster over this window
6080100120140Start $100$83$92
AKTS AMPH

AKTS vs AMPH: by the numbers

  • •AMPH is the larger company ($1.11B vs $975M market cap).
  • •AMPH is profitable (10.76% net margin) while AKTS runs a net loss (-727.04%).

Metrics side by side

Valuation

MetricAKTSAMPH
P/E ratioN/A14.89
Forward P/EN/A8.47
PEG ratioN/A0.11
P/S ratio96.941.52
P/B ratio2.011.44
EV / EBITDAN/A8.77
FCF yieldN/A13.78%

Profitability

MetricAKTSAMPH
Gross margin100.00%47.68%
Operating margin-1149.52%15.66%
Net margin-727.04%10.76%
ROE-15.09%10.23%
ROIC-16.54%5.93%

Growth (annualized)

MetricAKTSAMPH
Revenue CAGR (5Y)N/A13.71%
EPS CAGR (5Y)N/A134.23%
FCF CAGR (5Y)N/A23.90%
Total return CAGR (5Y)N/A6.13%

Frequently asked

Is AKTS or AMPH more profitable?
AMPH runs the higher net margin — AKTS at -727.04% versus AMPH at 10.76%.

Go deeper

Full AKTS analysisFull AMPH analysisInteractive comparison tool

Dig into the metrics

Amphastar Pharmaceuticals P/E ratioAktis Oncology ROEAmphastar Pharmaceuticals ROEAktis Oncology operating marginAmphastar Pharmaceuticals operating marginAktis Oncology revenue growthAmphastar Pharmaceuticals revenue growthAktis Oncology free cash flowAmphastar Pharmaceuticals free cash flow

Aktis Oncology & Amphastar Pharmaceuticals appear in these rankings

Highest FCF Yield StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.